Therefore, it seems that probably an indirect lowering of FGF23 levels through correction of iron deficiency, anemia, and hyperphosphatemia by iron-based phosphate binders and induction of more physiological EPO production might have a better effect than direct blocking of FGF23 signaling (Figure 3). The gene discussed is EPO; the disease is anemia.